Kawasaki’s disease (KD), once known as mucocutaneous lymph node syndrome, is a systemic inflammatory disorder occurring in children that is accompanied by vasculitis and a risk of coronary artery aneurysms.
Other typical features of KD include spiking fevers, cervical lymphadenopathy, conjunctivitis, erythematous changes on the lips and in the oral cavity, dryness and cracking of the lips, a strawberry appearance to the tongue, and a polymorphous rash.
Eighty percent of KD cases occur in children less than 5 years of age.
Attempts to link KD definitively to some types of infection, particularly ones associated with superantigens, have thus far been unsuccessful.
High dose aspirin and intravenous immune globulin (IVIG) are the cornerstones of therapy in KD. IVIG is essential to the prevention of coronary aneurysms.
■ Years after KD has occurred during childhood years, some cases of myocardial infarction caused by thrombosis of coronary aneurysms have been reported.
KeywordsKawasaki Disease American Heart Association Rheumatic Fever Coronary Artery Aneurysm Coronary Artery Abnormality
Unable to display preview. Download preview PDF.
- 3.Takahashi M. Kawasaki syndrome (mucocutaneous lymph node syndrome). In: Emmanouilides GC, ed. Moss and Adams heart disease in infants, children, and adolescents: including the fetus and young adult. 5th ed. Baltimore: Williams & Wilkins, 1995:13909.Google Scholar
- 4.Spector S. Scarlett fever, periarteritis nodosa, aneurysm of the coronary artery with spontaneous rupture, hemopericardium. Arch Pediatr 1939;25:319.Google Scholar
- 7.Japan Kawasaki Disease Research Committee. Diagnostic guideline of Kawasaki disease. Tokyo: Japan Kawasaki Disease Research Committee; 1984.Google Scholar
- 8.American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Diagnostic guidelines for Kawasaki disease. Am J Dis Child 1990;144:1218–1219.Google Scholar
- 12.Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Circulation 2004;110:2747–2771.PubMedCrossRefGoogle Scholar
- 13.Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Pediatrics 2004;114:1708–1733.PubMedCrossRefGoogle Scholar
- 15.Mason WH, Takahashi M, Schneider T. Recurrence of Kawasaki disease in a large urban cohort in the United States. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas: American Heart Association; 1993:21–26.Google Scholar
- 16.Taubert KA, Rowley AH, Shulman ST. A 10 year (1984-1993) United States hospital survey of Kawasaki disease. In: Kato H, ed. Kawasaki disease: proceedings of the 5th International Kawasaki Disease Symposium. New York: Elsevier; 1995:34–38.Google Scholar
- 28.Myones BL, Bathori JM, Tomita S, et al. Intravenous IgG infusions are associated with the in vitro inhibition of classical pathway-mediated lysis of sheep red blood cells and a decrease in C4d levels in Kawasaki disease. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Kawasaki Disease Symposium. Dallas: American Heart Association; 1993:412–418.Google Scholar